Details

Date:
Tuesday, December 5, 2023

Time:
In person
7:00 - 8:15AM - Networking & Continental Breakfast
8:30 - 10 AM - Program

Virtual
8:15 - 8:30 AM - Login & Networking
8:30 - 10 AM - Program

We can't wait for you to join us - in person or virtually - for one of The Boston Club's signature event - our annual Corporate Salute! This year's power-packed, hybrid event will take place on December 5, 2023. The theme of the Corporate Salute is Passion, Purpose, Breaking Barriers: A Conversation on Innovation and Breaking Barriers in Medicine and Biotechnology. We will celebrate the extraordinary impact of diverse women across business sectors, particularly in the health care and biotech industry.

We are thrilled that Noubar Afeyan, Co-Founder and Chairman of Moderna Therapeutics, will deliver special remarks for our audience. The program will feature an in-depth conversation between Sandra J. Horning, MD, retired Chief Medical Officer of Roche Inc. and a member of the Board of Directors at Moderna, Inc., and David Schenkein, MD, General Partner and Co-head of Life Science at GV and Chair of the Board of Directors of Agios Pharmaceuticals. They will focus on Dr. Horning's amazing professional journey and the passion with which she pursued her goals.

In addition to the engaging conversation between Drs. Horning and Schenkein, we will share the results of the 2023 Census of Women Directors and Executive Officers in Massachusetts’ Public Companies. And we will present the 2023 Women in Business Racial Equity Awards to two entrepreneurs making an impact in diversity, equity, and inclusion in our community.

Sponsors of The Boston Club’s Salute affirm their commitment to advancing women to senior leadership positions, and to supporting our work to ensure that more women are appointed to corporate boards. This event is eagerly anticipated by those corporations that recognize and reward the unique ways that women contribute to furthering and advancing the communities they serve within New England. For information on sponsorship and benefits, please email [email protected].

All registration is now CLOSED. Any questions about your participation? Please email [email protected].

Event Logistics for IN-PERSON Attendance

• If you registered to attend the event in person, you will receive a pre-registration email directly from PwC within 24 hours of the event. You must fill out the requested information in order to receive your QR code for entry to the event on December 5.
• When you arrive at the PwC building, you will be directed to the third floor for security check in. Have your QR code ready!
• If you are driving to the event, parking will be limited at the PwC building. There is ample parking at the Seaport Hotel two blocks away at 1 Seaport Lane, Boston. There are other public parking garages in the area as well.

PLEASE NOTE: Reservations are required for this event. No-shows and late cancellations for those registered to attend in person will be billed $100.00.  For this event, cancellations will be accepted until Noon on Thursday, November 30.

SPEAKERS BIOS: 

Sandra J. Horning, M.D. is internationally acknowledged as a leader in oncology research and pharmaceutical product development. As Chief Medical Officer and Global Head of Product Development at Roche, Inc. for ten years, Dr. Horning helped bring new medicines to patients in disease areas including cancer, multiple sclerosis, influenza, and blindness. Prior to her career at Roche, Dr. Horning spent 25 years as a practicing oncologist, investigator, and tenured professor at Stanford University Medical School and currently serves on several corporate boards, including the Board of Directors for Moderna, Inc. 

David Schenkein, M.D. a hematologist and oncologist for over 30 years, Dr. Schenkein is currently General Partner and co-head, Life Science at Google Ventures where he leads teams to maximize healthcare impact in areas including therapeutics, diagnostics, medical devices, novel care delivery systems, and payer innovation. Prior to joining GV, Dr. Schenkein served as CEO of Agios Pharmaceuticals, as well as in senior roles at Genentech and Millennium Pharmaceuticals.